Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors of paraneoplastic pemphigus.
Leger S, Picard D, Ingen-Housz-Oro S, Arnault JP, Aubin F, Carsuzaa F, Chaumentin G, Chevrant-Breton J, Chosidow O, Crickx B, D'incan M, Dandurand M, Debarbieux S, Delaporte E, Dereure O, Doutre MS, Guillet G, Jullien D, Kupfer I, Lacour JP, Leonard F, Lok C, Machet L, Martin L, Paul C, Pignon JM, Robert C, Thomas L, Weiller PJ, Ferranti V, Gilbert D, Courville P, Houivet E, Benichou J, Joly P. Leger S, et al. Arch Dermatol. 2012 Oct;148(10):1165-72. doi: 10.1001/archdermatol.2012.1830. Arch Dermatol. 2012. PMID: 22801794
A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.
Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, Vaillant L, D'Incan M, Plantin P, Bedane C, Young P, Bernard P; Bullous Diseases French Study Group. Joly P, et al. N Engl J Med. 2002 Jan 31;346(5):321-7. doi: 10.1056/NEJMoa011592. N Engl J Med. 2002. PMID: 11821508 Free article. Clinical Trial.
Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas.
Grange F, Petrella T, Beylot-Barry M, Joly P, D'Incan M, Delaunay M, Machet L, Avril MF, Dalac S, Bernard P, Carlotti A, Esteve E, Vergier B, Dechelotte P, Cassagnau E, Courville P, Saiag P, Laroche L, Bagot M, Wechsler J. Grange F, et al. Blood. 2004 May 15;103(10):3662-8. doi: 10.1182/blood-2003-08-2726. Epub 2004 Jan 15. Blood. 2004. PMID: 14726400 Free article.
Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera.
Joly P, Courville P, Lok C, Bernard P, Saiag P, Dreno B, Delaporte E, Bedane C, Picard C, Sassolas B, Plantin P, D'Incan M, Chosidow O, Pauwels C, Lambert D, Loche F, Prost C, Tancrede-Bohin E, Guillaume JC, Roujeau JC, Gilbert D, Tron F, Vaillant L; French Bullous Study Group. Joly P, et al. Dermatology. 2004;208(1):16-20. doi: 10.1159/000075040. Dermatology. 2004. PMID: 14730231
[Relationship between clinical findings of patients with bullous pemphigoid and antigens recognized by their circulating antibasement membrane zone antibodies].
Gary A, Carvalho P, Louison JB, Helot MF, Gilbert D, Bernard P, Roujeau JC, Bedane C, Delaporte E, Vaillant L, Dreno B, Saiag P, Tancrede-Bohin E, Plantin P, D'Incan M, Sassolas B, Lok C, Labeille B, Pauwels C, Chosidow O, Picard C, Loche F, Guillaume JC, Joly P. Gary A, et al. Ann Dermatol Venereol. 2004 Apr;131(4):333-7. doi: 10.1016/s0151-9638(04)93611-3. Ann Dermatol Venereol. 2004. PMID: 15258506 French.
Rituximab for pemphigus vulgaris.
Joly P, D'Incan M, Musette P. Joly P, et al. N Engl J Med. 2007 Feb 1;356(5):521; author reply 521-2. doi: 10.1056/NEJMc063290. N Engl J Med. 2007. PMID: 17267915 No abstract available.
A single cycle of rituximab for the treatment of severe pemphigus.
Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, Doutre MS, Delaporte E, Pauwels C, Franck N, Caux F, Picard C, Tancrede-Bohin E, Bernard P, Tron F, Hertl M, Musette P. Joly P, et al. N Engl J Med. 2007 Aug 9;357(6):545-52. doi: 10.1056/NEJMoa067752. N Engl J Med. 2007. PMID: 17687130 Free article. Clinical Trial.
224 results